Maze Therapeutics (NASDAQ:MAZE) Stock Jumps 5.5% - Still a Buy?

Key Points

• Maze Therapeutics shares rose 5.5% to about $29.05, although trading volume was 82% below the stock’s average daily volume.
• Analyst sentiment is broadly positive: the stock has a consensus “Buy” rating and a $64.45 average price target, with recent targets ranging from $48 to $110. However, Weiss Ratings maintained a “sell” rating.
• The company reported quarterly EPS of negative $0.76, in line with estimates, while insiders sold nearly 193,000 shares worth approximately $5.15 million during the last quarter.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s stock price shot up 5.5% during trading on Monday. The company traded as high as $28.49 and last traded at $29.0450. 122,329 shares were traded during trading, a decline of 82% from the average daily volume of 670,087 shares. The stock had previously closed at $27.53.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of recent research reports. Canaccord Genuity Group initiated coverage on shares of Maze Therapeutics in a report on Monday. They issued a "buy" rating and a $75.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Monday, September 21st. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. HC Wainwright reiterated a "buy" rating and issued a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 24th. Finally, Wedbush reissued an "outperform" rating and set a $48.00 price target on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $64.45.

Maze Therapeutics Stock Up 5.6%

The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The firm has a 50-day simple moving average of $26.76 and a 200 day simple moving average of $27.01. The stock has a market capitalization of $1.61 billion, a P/E ratio of -11.59 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). On average, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.70 EPS for the current year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the transaction, the insider directly owned 26,250 shares in the company, valued at approximately $723,975. This represents a 22.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the transaction, the chief executive officer owned 18,151 shares in the company, valued at $477,189.79. The trade was a 65.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 192,991 shares of company stock valued at $5,152,084 over the last quarter. Insiders own 5.30% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. increased its stake in Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company's stock valued at $150,182,000 after purchasing an additional 465,641 shares in the last quarter. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics during the second quarter worth approximately $133,502,907. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics during the second quarter worth approximately $122,983,582. BlackRock Inc. bought a new position in shares of Maze Therapeutics in the 2nd quarter worth $104,525,000. Finally, Jupiter Topco LLC acquired a new stake in Maze Therapeutics in the 2nd quarter valued at $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze's pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.